STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 3] JOHNSON & JOHNSON Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

John G. Morikis submitted an initial Form 3 disclosing beneficial ownership in Johnson & Johnson (JNJ). The filing reports direct ownership of 598.51 shares and indicates Mr. Morikis serves as a director of the issuer. The event requiring the statement is dated 09/08/2025 and the Form 3 was signed by an attorney-in-fact on 09/15/2025. The filing is an initial ownership disclosure under Section 16.

Positive
  • Director status disclosed, confirming the reporting person's governance role at JNJ
  • Initial Form 3 filed, providing required transparency about insider ownership
  • Direct ownership amount provided: 598.51 shares disclosed
  • Signed by attorney-in-fact, with signature date recorded (09/15/2025)
Negative
  • None.

Insights

TL;DR: Initial Section 16 disclosure showing a small, direct stake by a company director; neutral for valuation.

The Form 3 reports 598.51 shares owned directly by John G. Morikis and confirms his status as a director of Johnson & Johnson (JNJ). As an initial disclosure, it provides transparency about insider holdings but does not include transactions, option grants, or other compensatory details that would affect near-term financial analysis.

TL;DR: Routine governance disclosure establishing an insider's baseline holding; no material governance events disclosed.

The filing fulfills Section 16 reporting for a director by documenting direct ownership and providing dates: event dated 09/08/2025 with signature dated 09/15/2025. The signature on the form is by an attorney-in-fact, which is permitted. There are no indications of additional indirect holdings, derivative positions, or amendments.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
MORIKIS JOHN G

(Last) (First) (Middle)
ONE JOHNSON & JOHNSON PLAZA

(Street)
NEW BRUNSWICK NJ 08933

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2025
3. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [ JNJ ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 598.51 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Joleen Morgan, as attorney-in-fact for John Morikis 09/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many JNJ shares does John G. Morikis report owning?

The Form 3 reports 598.51 shares owned directly by John G. Morikis.

What is John G. Morikis's relationship to JNJ?

The filing indicates he is a director of Johnson & Johnson (JNJ).

When is the event date and when was the Form 3 signed?

The event requiring the statement is dated 09/08/2025 and the form shows a signature by an attorney-in-fact dated 09/15/2025.

Does the Form 3 disclose any derivative securities or indirect ownership?

No. The filing lists only direct ownership of common stock and reports no derivatives or indirect holdings.

Who signed the Form 3 on behalf of John G. Morikis?

The form is signed as /s/ Joleen Morgan, as attorney-in-fact for John Morikis.
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Latest SEC Filings

JNJ Stock Data

455.48B
2.41B
0.06%
74.37%
0.78%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK